Hyperhidrosis treatment follows a logical escalation: start with the least invasive, most evidence-based option and move up if the response is inadequate. This approach maximizes efficacy while minimizing unnecessary costs and side effects. Most patients find adequate control at an early step. This article maps the full ladder so patients and clinicians can make informed decisions about when to move to the next level.
Step 1: OTC Antiperspirants
The starting point for all patients. Clinical-strength OTC antiperspirants contain aluminum chloride hexahydrate at 12 to 15 percent concentration. Common brands include Certain Dri, some formulations of Drysol, and Secret Clinical Strength.
These products are effective for mild sweating in many patients. The concentration is lower than prescription formulations, which limits efficacy for moderate to severe cases. Most patients reading this article have already tried and found OTC products insufficient, making them appropriate candidates for prescription options.
Step 2: Prescription Aluminum Chloride
The first-line prescription option and the gold standard among topical treatments. Aluminum chloride at 20 to 25 percent is supported by strong clinical evidence. Applied nightly to completely dry skin under occlusion (wrapped in plastic wrap or a glove), it typically produces a 70 to 90 percent response rate for axillary (underarm) hyperhidrosis.
Less effective for palmar and plantar hyperhidrosis due to thicker skin and the difficulty of maintaining consistent overnight application on hands and feet. This should be the first prescription tried for the majority of patients with axillary hyperhidrosis.
Step 3: Topical Anticholinergics
When aluminum chloride provides insufficient control, or for patients with palmar, plantar, or facial hyperhidrosis where aluminum chloride performs poorly. Options include topical glycopyrronium (Qbrexza or compounded formulations) and topical oxybutynin gel.
These agents have a good clinical evidence base, particularly for facial and palmar hyperhidrosis. The topical application produces lower systemic side effects than oral anticholinergics because the drug is absorbed locally. This step represents escalation but maintains a relatively favorable side effect profile.
Step 4: Oral Anticholinergics
When topical treatments are insufficient, or when multiple body areas are affected simultaneously. Oral medications treat all sweating sites, unlike topicals which are applied locally. Options include oral glycopyrrolate and oral oxybutynin.
These are stronger and more systemic but carry higher side effect burden, including dry mouth, constipation, and urinary hesitancy. Requires careful titration starting at low doses and working up to find the optimal balance between efficacy and tolerability. This step demands clinical follow-up and monitoring.
Step 5: Iontophoresis
Particularly relevant for palmar and plantar hyperhidrosis. Can be used in parallel with other treatments rather than as a strict alternative. The evidence base is solid for hands and feet, with 70 to 80 percent response rates when the treatment protocol is followed consistently.
Requires sustained time commitment; the induction phase takes 2 to 3 weeks of frequent sessions, followed by ongoing maintenance. At-home devices are practical and cost-effective for long-term management. This step is non-pharmaceutical and has minimal systemic side effects.
Step 6: Botulinum Toxin Injections
Excellent efficacy for axillary, palmar, and plantar sites. FDA-approved for axillary hyperhidrosis. Duration of effect is 4 to 7 months, with the cycle repeating indefinitely. The primary barrier is cost; typical annual cost is 1,000 to 3,000 dollars without insurance coverage.
For patients who can access or afford it, botulinum toxin is highly effective. Insurance sometimes covers it with prior authorization after documented failure of topical treatments. This step represents meaningful financial commitment, which is why it comes after the less expensive topical options.
Step 7: miraDry and Surgical Options
miraDry is an FDA-cleared device using microwave energy to permanently destroy sweat glands in the axilla. Two sessions, 3 months apart, are typical. Results are usually permanent for the treated area. Cost is 3,000 to 4,000 dollars for both sessions and is not covered by insurance.
Endoscopic thoracic sympathectomy (ETS) is a surgical option that cuts the sympathetic nerves controlling sweating. It is effective but associated with compensatory sweating (sweating appearing in other body areas) in 70 to 90 percent of patients. Most specialists do not recommend ETS except in severe, treatment-refractory cases where the patient has been fully informed of the compensatory sweating risk.
The Clinical Takeaway
Most patients do not need to climb the entire ladder. The evidence-based sequence is: start at step 2 with prescription aluminum chloride. If inadequate response, add or switch to a topical anticholinergic (step 3). If still inadequate, consider oral anticholinergics (step 4). For palmar and plantar hyperhidrosis specifically, iontophoresis (step 5) is highly effective and should be offered when topicals have failed.
Botulinum toxin (step 6) is for patients who need more than topicals can provide and have the financial means or insurance coverage. Steps 6 and 7 are reserved for treatment-refractory cases. The ladder exists to give patients a roadmap, not to imply that everyone should climb it. Starting at step 2 and titrating up to step 3 or 4 covers the large majority of cases effectively.